

**Danyelza (naxitamab-ggqk)
Effective 01/01/2023**

Plan	<input checked="" type="checkbox"/> MassHealth (UPPL) <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Neuroblastoma is a cancer in which malignant cells form in the neuroblasts in the adrenal glands, neck, chest, or spinal cord.

Danyelza is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

No PA	Drugs that require PA
Unituxin [®] (dinutuximab) ^H	Danyelza [®] (naxitamab-ggqk)

^H This drug is available only in an inpatient hospital setting.

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when **ALL** the following criteria are met, and documentation is provided:

Neuroblastoma of Bone or Bone Marrow

1. Appropriate diagnosis
2. Prescriber is an oncologist
3. Appropriate dosing

4. The member is ≥ 1 year of age
5. The member's tumor is high risk
6. The member had demonstrated a partial response, minor response, or stable disease to prior treatment (e.g., vincristine, cyclophosphamide, topotecan, doxorubicin, cisplatin, and etoposide)
7. The requested medication will be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) agent

Continuation of Therapy

Reauthorization by physician will infer a positive response to therapy.

Limitations

Initial approvals and reauthorizations will be for 6 months.

Drug	Dosing
Danyelza [®] (naxitamab-gqgk) Vial: 40 mg/10 mL	2 mg/kg/day (up to 150 mg/day) on Days 1, 3, and 5 of each treatment cycle, administered as an IV infusion after dilution in combination with GM-CSF SC Treatment cycles are repeated every four weeks until complete response or partial response, followed by five additional cycles every four weeks. Subsequent cycles may be repeated every eight weeks.

GM-CSF=granulocyte-macrophage colony-stimulating factor, IV=intravenous, SC=subcutaneous

References

1. Danyelza[®] (naxitamab-gqgk) [prescribing information]. New York (NY): Y-mAbs Therapeutics, Inc.; 2020 Nov.
2. FDA Approves Y-mAbs' DANYELZA[®] (naxitamab-gqgk) for the Treatment of Neuroblastoma [press release on the internet]. Pipeline Review; 2020 Nov 26 [cited 2021 Feb 21]. Available from: <https://pipelinereview.com/index.php/2020112676664/Antibodies/FDA-Approves-Y-mAbs-DANYELZA-naxitamab-gqgk-for-the-Treatment-of-Neuroblastoma.html>.
3. Key Statistics About Neuroblastoma [webpage on the internet]. American Cancer Society; 2020 Jan 8 [cited 2021 Feb 21]. Available from: <https://www.cancer.org/cancer/neuroblastoma/about/key-statistics.html>.
4. Unituxin[®] (dinutixumab) [prescribing information]. Research Triangle Park (NC): United Therapeutics Corp; 2020 Sept.
5. Shohet JM, Lowas SR, Nuchtern JG. Treatment and prognosis of neuroblastoma. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2021 Nov [cited 2021 Dec 20]. Available from: <https://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma>.

Review History

09/21/2022 – Reviewed and Created for Sept P&T; matched MH UPPL.

Disclaimer



AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.